"USANA Health Sciences: High-Quality Formulations, Lowered Share Value"

"USANA Health Sciences: High-Quality Formulations, Lowered Share Value"

USANA Health Sciences, a leading nutritional supplement company with over three decades of experience, is currently undergoing a significant transformation. The company, which boasts a pristine balance sheet with $182 million of cash and minimal debt, has recently acquired a 78.8% stake in Hiya Health Products, a children's health and wellness company. This strategic move is central to USANA's shift away from its traditional multi-level marketing (MLM) model towards a diversified, omnichannel approach that includes direct-to-consumer sales.

In the first quarter of 2025, USANA reported net sales of $250 million, a 10% year-over-year increase. Hiya, with its direct-to-consumer business and 224,000 active monthly subscribers, contributed $37 million to these sales. However, the company faced margin pressures due to Hiya's lower gross margins and integration-related costs. Adjusted EBITDA declined by 10% year-over-year to $30 million, as investors await clarity on when Hiya’s scale and synergy benefits will offset these costs and improve overall profitability.

The Asia-Pacific region, accounting for 70% of USANA's sales, remains the company's financial backbone. However, geopolitical and currency risks persist, particularly in the Americas and Europe markets, which are underperforming, requiring strategic repositioning.

Looking ahead, USANA plans to leverage product synergies by cross-selling Hiya’s children’s wellness products within its existing direct-selling network to deepen customer engagement and unlock new revenue streams. The company aims to capitalise on the high-growth children's wellness market through Hiya, while gradually diversifying away from strict dependence on its traditional MLM structure. This pivot is seen as a strategic inflection point towards renewed growth and relevance.

USANA has reaffirmed its 2025 fiscal outlook, targeting consolidated net sales between $920 million and $1 billion and adjusted diluted EPS ranging from $2.35 to $3.00. Potential headwinds include trade uncertainties and tariffs, especially relating to raw materials between the US and China. Share repurchases, which were paused during the Hiya acquisition, are expected to resume once integration stabilises, reflecting management’s commitment to shareholder value.

USANA's valuation is lower than that of consumer health peers and even its own historical average. The company's EV/Sales is a decent 0.48×, and its price-to-free-cash-flow is at approximately 12×. A re-rating of USANA's stock to its historical P/E of ~15x on $2.70 adj EPS would mean a $40 stock, 33% higher from its current price.

USANA's strength lies in pairing high-quality products with a deep global distributor network on a multi-level marketing platform. The company operates in the nutritional supplement sector and produces and distributes a range of dietary supplements, functional foods, and skincare products. USANA Health Sciences was founded by microbiologist Dr. Myron Wentz in 1992.

The acquisition of Hiya Health not only provides revenue expansion but also access to a digital-native brand that avoids traditional MLM distribution. USANA's management has historically shunned dilutive capital raisings and used internal funding to finance growth and repurchases. The company has more than $60 million of authorized share buyback capacity and a robust free cash flow, allowing for the retirement of 8-10% of shares in the next 18 months.

However, USANA is substantially exposed to Chinese consumer sentiment and regulatory views, making China a significant risk factor. The company earns over 75% of its revenues from the Asia Pacific, with China alone accounting for over half. Competitors such as Nu Skin and Herbalife face their own challenges, with Nu Skin at 0.3× EV/Sales and below 6× forward P/E, indicating problems of sustainability and margin decline, and Herbalife below 4.5× EV/EBITDA but with significant financial leverage and reputational risk.

In summary, USANA Health Sciences is in a phase of transformative growth, seeking to blend its established presence in nutritional supplements with a direct-to-consumer model via Hiya. While initial financial impacts include margin pressure, the company is positioned to enhance profitability through product synergies and geographic expansion, signaling a promising future as it moves away from its traditional MLM framework towards a more diversified, omnichannel health and wellness enterprise.

1. USANA Health Sciences, a company with a strong background in nutritional supplements, aims to diversify its business model by leveraging the synergies of its recent acquisition of Hiya Health Products, a children's health and wellness company.
2. USANA's strategic move towards a diversified, omnichannel approach, which includes direct-to-consumer sales, is central to its shift away from its traditional multi-level marketing model.
3. The company's acquisition of Hiya Health not only provides revenue expansion but also access to a digital-native brand that avoids traditional MLM distribution.
4. USANA's valuation, despite being lower than that of consumer health peers and even its own historical average, presents an opportunity for re-rating, potentially boosting its stock price by 33%.
5. The company operates in the health-and-wellness sector, producing and distributing a range of dietary supplements, functional foods, and skincare products. Its strength lies in pairing high-quality products with a deep global distributor network.

Read also: